Overview

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Status:
Terminated

Trial end date:
2020-09-25

Target enrollment:

Participant gender:

Summary

This is a pilot study to explore the effects of pimavanserin and low-dose quetiapine in subjects with Parkinson's disease with neuropsychiatric symptoms.

Phase:

Phase 2

Details

Lead Sponsor:

ACADIA Pharmaceuticals Inc.

Treatments:

Pimavanserin
Quetiapine Fumarate